Croda International PLC - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Croda International PLC



Croda International Plc is a UK-based manufacturer and worldwide supplier of oleochemicals offering one of the widest ranges of chemical specialties, surfactants, and high-purity lipids available to the pharmaceutical industry with products manufactured at multiple sites throughout the world.

Croda manufactures excipients of superior quality and purity for the global pharmaceutical market. Croda developed and utilises a proprietary flash chromatographic process called Super Refining. This process physically removes impurities from pharmaceutical excipients without altering their fundamental structure in any way. This process allows the offering of a range of high purity excipients that can improve API and formulation stability.

Croda offers a complete range of products for topical dosage forms as well as high-purity multicompendial solvents, solubilisers and surfactants suitable for parenteral, oral and ophthalmic formulations. Featured products include Super Refined ingredients: Oils, Oleic Acid, Oleyl Alcohol, Isopropyl Myristate, PEGs, Polysorbates, Dimethyl Isosorbide, Medical Grade Lanolins, Poloxamers and Omega 3 Fatty Acid Concentrates.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here